Utilization of biodegradable polymeric materials as delivery agents in dermatology

Clinical, Cosmetic and Investigational Dermatology

Volumn 7, Issue , 2014, Pages 23-34

  Rancan, Fiorenza ^a   Blume Peytavi, Ulrike ^a   Vogt, Annika ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biodegradable polymers; Hair follicles; Nanocarriers; Nanoparticles; Skin penetration

Indexed keywords

ANTIINFLAMMATORY AGENT; BIODEGRADABLE POLYMER; CHITOSAN; DENDRIMER; DRUG CARRIER; FLUFENAMIC ACID; GLUCOCORTICOID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; KETOPROFEN; LIPOSOME; MICROSPHERE; NANOCARRIER; NONSTEROID ANTIINFLAMMATORY AGENT; POLYAMIDOAMINE; POLYCAPROLACTONE; POLYGLACTIN; POLYMER; RETINOID; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; SPANTIDE; TACROLIMUS; UNCLASSIFIED DRUG;

ACNE; ATOPIC DERMATITIS; CONTACT DERMATITIS; DERMATOLOGY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; ENCAPSULATION; ENDOCYTOSIS; GENE THERAPY; HAIR FOLLICLE; HUMAN; HYDROGEL; INTERNALIZATION; NONHUMAN; PAIN; PSORIASIS; REVIEW; SKIN ALLERGY; SKIN ATROPHY; SKIN CANCER; SKIN DISEASE; SKIN INFECTION; SKIN IRRITATION; SKIN PENETRATION; SKIN PERMEABILITY; STRATUM CORNEUM; SUSTAINED DRUG RELEASE;

EID: 84892155629     PISSN: 11787015     EISSN: None     Source Type: Journal    
DOI: 10.2147/CCID.S39559     Document Type: Review

References (109)

1. Papakostas D, Rancan F, Sterry W, Blume-Peytavi U, Vogt A. Nanoparticles in dermatology. Arch Dermatol Res. 2011;303(8): 533-550.
2. Egbaria K, Weiner N. Liposomes as a topical drug delivery system. Adv Drug Deliver Rev. 1990;5(3):287-300.
3. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev. 2002;54 Suppl 1:S131-S155.
4. Guterres SS, Alves MP, Pohlmann AR. Polymeric nanoparticles, nanospheres and nanocapsules, for cutaneous applications. Drug Target Insights. 2007;2:147-157.
5. Zhong SP, Zhang YZ, Lim CT. Tissue scaffolds for skin wound healing and dermal reconstruction. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010;2(5):510-525.
6. Venugopal J, Ramakrishna S. Biocompatible nanofiber matrices for the engineering of a dermal substitute for skin regeneration. Tissue Eng. 2005;11(5-6):847-854.
7. Ekaputra AK, Prestwich GD, Cool SM, Hutmacher DW. The threedimensional vascularization of growth factor-releasing hybrid scaffold of poly (epsilon-caprolactone)/collagen fibers and hyaluronic acid hydrogel. Biomaterials. 2011;32(32):8108-8117.
8. Hadjizadeh A, Doillon CJ. Directional migration of endothelial cells towards angiogenesis using polymer fibres in a 3D co-culture system. J Tissue Eng Regen Med. 2010;4(7):524-531.
9. Wichterle O, Lim D. Hydrophilic gels for biological use. Nature. 1960;185:117-118.
10. Hoffman AS. Hydrogels for biomedical applications. Adv Drug Deliv Rev. 2002;54(1):3-12.
11. Arts JH, Muijser H, Duistermaat E, Junker K, Kuper CF. Five-day inhalation toxicity study of three types of synthetic amorphous silicas in Wistar rats and post-exposure evaluations for up to 3 months. Food Chem Toxicol. 2007;45(10):1856-1867.
12. Bettencourt A, Almeida AJ. Poly(methyl methacrylate) particulate carriers in drug delivery. J Microencapsul. 2012;29(4):353-367.
13. Rehman K, Zulfakar MH. Recent advances in gel technologies for topical and transdermal drug delivery. Drug Dev Ind Pharm. 2013.
14. Chen X, Peng LH, Shan YH, et al. Astragaloside IV-loaded nanoparticleenriched hydrogel induces wound healing and anti-scar activity through topical delivery. Int J Pharm. 2013;447(1-2):171-181.
15. Moya-Ortega MD, Alvarez-Lorenzo C, Concheiro A, Loftsson T. Cyclodextrin-based nanogels for pharmaceutical and biomedical applications. Int J Pharm. 2012;428(1-2):152-163.
16. Asadian-Birjand M, Sousa-Herves A, Steinhilber D, Cuggino JC, Calderon M. Functional nanogels for biomedical applications. Curr Med Chem. 2012;19(29):5029-5043.
17. Sasaki Y, Akiyoshi K. Nanogel engineering for new nanobiomaterials: from chaperoning engineering to biomedical applications. Chem Rec. 2010;10(6):366-376.
18. Dang JM, Leong KW. Natural polymers for gene delivery and tissue engineering. Adv Drug Deliv Rev. 2006;58(4):487-499.
19. Elzoghby AO, Samy WM, Elgindy NA. Protein-based nanocarriers as promising drug and gene delivery systems. J Control Release. 2012; 161(1):38-49.
20. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310-1316.
21. Feng Y, Lu J, Behl M, Lendlein A. Progress in depsipeptide-based biomaterials. Macromol Biosci. 2010;10(9):1008-1021.
22. Fahmy TM, Demento SL, Caplan MJ, Mellman I, Saltzman WM. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine (Lond). 2008;3(3):343-355.
23. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3): 329-347.
24. Luengo J, Weiss B, Schneider M, et al. Influence of nanoencapsulation on human skin transport of flufenamic acid. Skin Pharmacol Physiol. 2006;19(4):190-197.
25. Brannon-Peppas L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug delivery. Int J Pharm. 1995;116(1):1-9.
26. Rösler A, Vandermeulen GW, Klok HA. Advanced drug delivery devices via self-assembly of amphiphilic block copolymers. Adv Drug Deliv Rev. 2001;53(1):95-108.
27. Stiriba SE, Frey H, Haag R. Dendritic polymers in biomedical applications: from potential to clinical use in diagnostics and therapy. Angew Chem Int Ed Engl. 2002;41(8):1329-1334.
28. Michaels AS, Chandrasekaran SK, Shaw JE. Drug permeation through human skin: theory and in vitro experimental measurement. AICHE J. 1975;21(5):985-996.
29. Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol. 2008;17(12):1063-1072.
30. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Adv Drug Deliv Rev. 2002;54 Suppl 1:S41-S55.
31. Schmid-Wendtner MH, Korting HC. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol. 2006;19(6): 296-302.
32. Rawlings AV, Voegeli R. Stratum corneum proteases and dry skin conditions. Cell Tissue Res. 2013;351(2):217-235.
33. Simonetti O, Hoogstraate AJ, Bialik W, et al. Visualization of diffusion pathways across the stratum corneum of native and in-vitroreconstructed epidermis by confocal laser scanning microscopy. Arch Dermatol Res. 1995;287(5):465-473.
34. Wang TF, Kasting GB, Nitsche JM. A multiphase microscopic dif- fusion model for stratum corneum permeability. II. Estimation of physicochemical parameters, and application to a large permeability database. J Pharm Sci. 2007;96(11):3024-3051.
35. Lademann J, Knorr F, Richter H, et al. Hair follicles - an efficient storage and penetration pathway for topically applied substances. Summary of recent results obtained at the Center of Experimental and Applied Cutaneous Physiology, Charité-Universitätsmedizin Berlin, Germany. Skin Pharmacol Physiol. 2008;21(3):150-155.
36. Szabo G. The number of eccrine sweat glands in human skin. Adv Biol Skin. 1962;3:1-5.
37. Lademann J, Richter H, Teichmann A, et al. Nanoparticles - an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm. 2007;66(2):159-164.
38. Vogt A, Hadam S, Heiderhoff M, et al. Morphometry of human terminal and vellus hair follicles. Exp Dermatol. 2007;16(11):946-950.
39. Schwartz JR, Shah R, Krigbaum H, Sacha J, Vogt A, Blume-Peytavi U. New insights on dandruff/seborrhoeic dermatitis: the role of the scalp follicular infundibulum in effective treatment strategies. Br J Dermatol. 2011;165 Suppl 2:18-23.
40. Blume-Peytavi U, Massoudy L, Patzelt A, et al. Follicular and percutaneous penetration pathways of topically applied minoxidil foam. Eur J Pharm Biopharm. 2010;76(3):450-453.
41. Trauer S, Lademann J, Knorr F, et al. Development of an in vitro modified skin absorption test for the investigation of the follicular penetration pathway of caffeine. Skin Pharmacol Physiol. 2010;23(6):320-327.
42. Toll R, Jacobi U, Richter H, Lademann J, Schaefer H, Blume-Peytavi U. Penetration profile of microspheres in follicular targeting of terminal hair follicles. J Invest Dermatol. 2004;123(1):168-176.
43. Watkinson AC, Bunge AL, Hadgraft J, Lane ME. Nanoparticles do not penetrate human skin - a theoretical perspective. Pharm Res. 2013;30(8):1943-1946.
44. Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J Pharm Sci. 2010;99(1):21-50.
45. Nohynek GJ, Lademann J, Ribaud C, Roberts MS. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Crit Rev Toxicol. 2007;37(3):251-277.
46. Schreier H, Bouwstra J. Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery. J Control Rel. 1994;30(1):1-15.
47. Fang JY, Hong CT, Chiu WT, Wang YY. Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm. 2001;219(1-2): 61-72.
48. Samah NA, Williams N, Heard CM. Nanogel particulates located within diffusion cell receptor phases following topical application demonstrates uptake into and migration across skin. Int J Pharm. 2010; 401(1-2):72-78.
49. Zhang LW, Monteiro-Riviere NA. Assessment of quantum dot penetration into intact, tape-stripped, abraded and flexed rat skin. Skin Pharmacol Physiol. 2008;21(3):166-180.
50. Prow TW, Monteiro-Riviere NA, Inman AO, et al. Quantum dot penetration into viable human skin. Nanotoxicology. 2012;6(2): 173-185.
51. Lane ME. Skin penetration enhancers. Int J Pharm. 2013;447(1-2): 12-21.
52. Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 2004;56(5):581-587.
53. Lin LL, Grice JE, Butler MK, et al. Time-correlated single photon counting for simultaneous monitoring of zinc oxide nanoparticles and NAD(P)H in intact and barrier-disrupted volunteer skin. Pharm Res. 2011;28(11):2920-2930.
54. Shah PP, Desai PR, Patel AR, Singh MS. Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs. Biomaterials. 2012;33(5):1607-1617.
55. Kang MJ, Eum JY, Jeong MS, et al. Facilitated skin permeation of oregonin by elastic liposomal formulations and suppression of atopic dermatitis in NC/Nga mice. Biol Pharm Bull. 2010;33(1):100-106.
56. Abdel-Mottaleb MM, Moulari B, Beduneau A, Pellequer Y, Lamprecht A. Nanoparticles enhance therapeutic outcome in inflamed skin therapy. Eur J Pharm Biopharm. 2012;82(1):151-157.
57. Rouvière PE, Li J, Brill DJ, et al. Bionanotechnology application of polypeptides in a hair color product: self-assembly enables expression, processing, and functionality. Biotechnol J. 2013;8(2):247-256.
58. Vogt A, Combadiere B, Hadam S, et al. 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol. 2006;126(6):1316-1322.
59. Rancan F, Gao Q, Graf C, et al. Skin penetration and cellular uptake of amorphous silica nanoparticles with variable size, surface functionalization, and colloidal stability. ACS Nano. 2012;6(8):6829-6842.
60. Mortensen LJ, Oberdörster G, Pentland AP, Delouise LA. In vivo skin penetration of quantum dot nanoparticles in the murine model: the effect of UVR. Nano Lett. 2008;8(9):2779-2787.
61. Mahe B, Vogt A, Liard C, et al. Nanoparticle-based targeting of vaccine compounds to skin antigen-presenting cells by hair follicles and their transport in mice. J Invest Dermatol. 2009;129(5):1156-1164.
62. O'Regan GM, Sandilands A, McLean WH, Irvine AD. Filaggrin in atopic dermatitis. J Allergy Clin Immunol. 2009;124(3 Suppl 2): R2-R6.
63. Yanagisawa R, Takano H, Inoue KI, Koike E, Sadakane K, Ichinose T. Size effects of polystyrene nanoparticles on atopic dermatitislike skin lesions in NC/NGA mice. Int J Immunopathol Pharmacol. 2010; 23(1):131-141.
64. Kirschner N, Poetzl C, von den Driesch P, et al. Alteration of tight junction proteins is an early event in psoriasis: putative involvement of proinflammatory cytokines. Am J Pathol. 2009;175(3):1095-1106.
65. Prow TW, Grice JE, Lin LL, et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011;63(6):470-491.
66. Baldo A, Monod M, Mathy A, et al. Mechanisms of skin adherence and invasion by dermatophytes. Mycoses. 2012;55(3):218-223.
67. Baumann L. Skin ageing and its treatment. J Pathol. 2007;211(2): 241-251.
68. Ghadially R, Brown BE, Sequeira-Martin SM, Feingold KR, Elias PM. The aged epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in humans and a senescent murine model. J Clin Invest. 1995;95(5):2281-2290.
69. Tezuka T, Qing J, Saheki M, Kusuda S, Takahashi M. Terminal differentiation of facial epidermis of the aged: immunohistochemical studies. Dermatology. 1994;188(1):21-24.
70. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003;422(6927):37-44.
71. Zhang LW, Monteiro-Riviere NA. Mechanisms of quantum dot nanoparticle cellular uptake. Toxicol Sci. 2009;110(1):138-155.
72. Kettiger H, Schipanski A, Wick P, Huwyler J. Engineered nanomaterial uptake and tissue distribution: from cell to organism. Int J Nanomedicine. 2013;8:3255-3269.
73. Luten J, van Nostrum CF, De Smedt SC, Hennink WE. Biodegradable polymers as non-viral carriers for plasmid DNA delivery. J Control Release. 2008;126(2):97-110.
74. Azevedo HS, Reis RL. Understanding the Enzymatic Degradation of Biodegradable Polymers and Strategies to Control their Degradation Rate. Biodegradable Systems in Tissue Engineering and Regenerative Medicine. Boca Raton: CRC Press; 2005:177-201.
75. Mansour AM, Drevs J, Esser N, et al. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res. 2003;63(14):4062-4066.
76. Yoo HS, Lee EA, Park TG. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J Control Release. 2002;82(1):17-27.
77. Weng H, Zhou J, Tang L, Hu Z. Tissue responses to thermallyresponsive hydrogel nanoparticles. J Biomater Sci Polym Ed. 2004;15(9):1167-1180.
78. Küchler S, Radowski MR, Blaschke T, et al. Nanoparticles for skin penetration enhancement - a comparison of a dendritic core-multishellnanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm. 2009;71(2):243-250.
79. Küchler S, Abdel-Mottaleb M, Lamprecht A, Radowski MR, Haag R, Schäfer-Korting M. Influence of nanocarrier type and size on skin delivery of hydrophilic agents. Int J Pharm. 2009;377(1-2):169-172.
80. Chiang A, Tudela E, Maibach HI. Percutaneous absorption in diseased skin: an overview. J Appl Toxicol. 2012;32(8):537-563.
81. Hussain Z, Katas H, Mohd Amin MC, Kumolosasi E, Buang F, Sahudin S. Self-assembled polymeric nanoparticles for percutaneous co-delivery of hydrocortisone/hydroxytyrosol: an ex vivo and in vivo study using an NC/Nga mouse model. Int J Pharm. 2013;444(1-2):109-119.
82. Jaques JA, Rezer JF, Ruchel JB, et al. An experimental model of contact dermatitis: evaluation of the oxidative profile of Wistar rats treated with free and nanoencapsulated clobetasol. Redox Rep. 2012;17(5): 206-213.
83. Chu CC, Di Meglio P, Nestle FO. Harnessing dendritic cells in inflammatory skin diseases. Semin Immunol. 2011;23(1):28-41.
84. Bak RO, Mikkelsen JG. Regulation of cytokines by small RNAs during skin inflammation. J Biomed Sci. 2010;17:53.
85. Friedman AJ, Han G, Navati MS, et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide. 2008;19(1):12-20.
86. Lansdown AB. Silver. I: Its antibacterial properties and mechanism of action. J Wound Care. 2002;11(4):125-130.
87. Rujitanaroj PO, Pimpha N, Supaphol P. Wound-dressing materials with antibacterial activity from electrospun gelatin fiber mats containing silver nanoparticles. Polymer. 2008;49(21):4723-4732.
88. Shim J, Seok Kang H, Park WS, Han SH, Kim J, Chang IS. Transdermal delivery of mixnoxidil with block copolymer nanoparticles. J Control Release. 2004;97(3):477-484.
89. Knorr F, Lademann J, Patzelt A, Sterry W, Blume-Peytavi U, Vogt A. Follicular transport route - research progress and future perspectives. Eur J Pharm Biopharm. 2009;71(2):173-180.
90. Rancan F, Todorova A, Hadam S, et al. Stability of polylactic acid particles and release of fluorochromes upon topical application on human skin explants. Eur J Pharm Biopharm. 2012;80(1):76-84.
91. Rancan F, Papakostas D, Hadam S, et al. Investigation of polylactic acid (PLA) nanoparticles as drug delivery systems for local dermatotherapy. Pharm Res. 2009;26(8):2027-2036.
92. Cho HK, Cho JH, Choi SW, Cheong IW. Topical delivery of retinol emulsions co-stabilised by PEO-PCL-PEO triblock copolymers: effect of PCL block length. J Microencapsul. 2012;29(8):739-746.
93. Ridolfi DM, Marcato PD, Justo GZ, Cordi L, Machado D, Durán N. Chitosan-solid lipid nanoparticles as carriers for topical delivery of tretinoin. Colloids Surf B Biointerfaces. 2012;93:36-40.
94. Nakamura M, Jo J, Tabata Y, Ishikawa O. Controlled delivery of T-box21 small interfering RNA ameliorates autoimmune alopecia (Alopecia Areata) in a C3H/HeJ mouse model. Am J Pathol. 2008;172(3):650-658.
95. Romero EL, Morilla MJ. Highly deformable and highly fluid vesicles as potential drug delivery systems: theoretical and practical considerations. Int J Nanomedicine. 2013;8:3171-3186.
96. Zampieri AL, Ferreira FS, Resende EC, et al. Biodegradable polymeric nanocapsules based on poly(DL-lactide) for genistein topical delivery: obtention, characterization and skin permeation studies. J Biomed Nanotechnol. 2013;9(3):527-534.
97. Venuganti VV, Perumal OP. Effect of poly(amidoamine) (PAMAM) dendrimer on skin permeation of 5-fluorouracil. Int J Pharm. 2008; 361(1-2):230-238.
98. Zhao QH, Zhang Y, Liu Y, et al. Anticancer effect of realgar nanoparticles on mouse melanoma skin cancer in vivo via transdermal drug delivery. Med Oncol. 2010;27(2):203-212.
99. Casas A, Battah S, Di Venosa G, et al. Sustained and efficient porphyrin generation in vivo using dendrimer conjugates of 5-ALA for photodynamic therapy. J Control Release. 2009;135(2): 136-143.
100. Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 2006;27(12):573-579.
101. Duffy D, Perrin H, Abadie V, et al. Neutrophils transport antigen from the dermis to the bone marrow, initiating a source of memory CD8+ T cells. Immunity. 2012;37(5):917-929.
102. Liard C, Munier S, Arias M, et al. Targeting of HIV-p24 particlebased vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine. 2011;29(37):6379-6391.
103. Hansen S, Lehr CM. Nanoparticles for transcutaneous vaccination. Microb Biotechnol. 2012;5(2):156-167.
104. Matsuo K, Hirobe S, Okada N, Nakagawa S. Frontiers of transcutaneous vaccination systems: novel technologies and devices for vaccine delivery. Vaccine. 2013;31(19):2403-2415.
105. Li J, Li X, Zhang Y, et al. Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome. J Gene Med. 2010;12(6):481-490.
106. Özbaş-Turan S, Akbug̃a J. Plasmid DNA-loaded chitosan/TPP nanoparticles for topical gene delivery. Drug Deliv. 2011;18(3): 215-222.
107. Aissaoui A, Chami M, Hussein M, Miller AD. Efficient topical delivery of plasmid DNA to lung in vivo mediated by putative triggered, PEGylated pDNA nanoparticles. J Control Release. 2011;154(3): 275-284.
108. Zheng D, Giljohann DA, Chen DL, et al. Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci U S A. 2012;109(30):11975-11980.
109. Segura T. Formulations and Delivery Limitations of Nucleic-Acid-Based Therapies. Handbook of Pharmaceutical Biotechnology. 2010;1013-1059.